These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 15860093

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.
    Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, Verputten M, O'Brien DP.
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):60-7. PubMed ID: 19211930
    [Abstract] [Full Text] [Related]

  • 4. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K.
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, Ciaffi L, Brulet C, Peytavin G, Vergne L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    AIDS; 2007 Mar 30; 21(6):768-71. PubMed ID: 17413701
    [Abstract] [Full Text] [Related]

  • 6. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D, Apisarnthanarak A, Laowansiri P, Mundy LM.
    HIV Med; 2008 Oct 30; 9(8):636-41. PubMed ID: 18643857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P.
    Bull Soc Pathol Exot; 2008 Dec 30; 101(5):404-6. PubMed ID: 19192611
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 30; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 11. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    Antivir Ther; 2005 Apr 30; 10(2):335-41. PubMed ID: 15865228
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 30; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 14. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Feb 15; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 16. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.
    Clin Infect Dis; 2007 Feb 01; 44(3):447-52. PubMed ID: 17205457
    [Abstract] [Full Text] [Related]

  • 17. Developing countries need better antiretroviral drugs.
    Mykén N, Sundbeck B, Mpumilwa G, Andersson R.
    J Int Assoc Physicians AIDS Care (Chic); 2009 Feb 01; 8(1):23-4. PubMed ID: 19171914
    [No Abstract] [Full Text] [Related]

  • 18. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 19. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, Mougnutou R, Nkoué N, Calmy A, Koulla-Shiro S, Delaporte E.
    AIDS Res Hum Retroviruses; 2008 Mar 15; 24(3):393-9. PubMed ID: 18327976
    [Abstract] [Full Text] [Related]

  • 20. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO.
    Niger J Clin Pract; 2008 Dec 15; 11(4):312-5. PubMed ID: 19320401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.